Keywords: Tumors (Post-Treatment), Endocrine, Pituitary prolactinoma
Motivation: Predicting and managing dopamine agonists (DA) resistance of prolactinomas remain a challenge. There is no reliable quantitative imaging marker.
Goal(s): The goal is to use accelerated quantitative T2 mapping(GRAPPATNI) for early diagnosis of drug resistance in pituitary prolactinomas to guide treatment.
Approach: This is a cross-sectional study. It will analyze the differences in T2 values between drug-resistant and sensitive groups and explore their diagnostic value in predicting drug sensitivity.
Results: Quantitative T2 values have better sensitivity than T2 signal intensity (SI) in predicting drug resistance in pituitary prolactinoma.
Impact: This is the first study to apply GRAPPATINI in prolactinoma. We found that T2 values of tumors were lower in drug-resistant prolactinoma than sensitive patients. T2 values might be a promising predictive imaging tool.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords